Skip to content
Head to head

Absci Corp vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ABSI · VRTX

Updated 4 minutes ago

1-year performance, rebased to 100

ABSI +162.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
ABSIVRTX
Snapshot
Sector--Biotechnology
Last price7.51515.02
Change today-7.97%-1.08%
1-year return+171.1%+22.0%
Market cap$1.30B$130.58B
52-week range2.24 – 12.54412.27 – 568.67
Valuation
P/E (TTM)-9.5133.14
P/E percentile, own 5-yr range6th99th
P/B5.936.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.8415.32
Net profit (TTM)$-145.11M$3.88B
Revenue (TTM)$1.49M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-19.6%+11.8%
Gross margin--85.5%
Operating margin-9155.3%33.1%
Net margin-8451.3%30.7%
Free cash flow (TTM)$-112.46M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership96.9%96.8%
Insider activity (12mo)30 buy / 20 sell28 buy / 22 sell
Short interest (% of float)20.9%1.9%
Analyst consensus89% buy / 11% hold (9)95% buy / 5% hold (21)
Analyst price target$15 (+96%)$624 (+21%)
StockVane view
StockVane Quant RatingC (99)C (68)
Company
Employees1406,400
Founded20111989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.